Shots:

• RemeGen has enrolled the first patient under the P-III clinical evaluation of telitacicept as a treatment of generalized myasthenia gravis (gMG) across the US
• The P-III is a multicenter, randomized, double-blind trial to assess the safety & effectiveness of telitacicept for treating gMG among 180 subjects from various regions
• Telitacicept, an antibody fusion protein, works by targeting BLyS and APRIL to reduce pathogenic antibodies by attacking B cells and plasma cells. Preliminary clinical studies show it can effectively and continuously improve the patients’ conditions